Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Fate Therapeutics stock | 52.8

Own Fate Therapeutics stock in just a few minutes.


Fact checked

Fate Therapeutics, Inc is a biotechnology business based in the US. Fate Therapeutics shares (FATE) are listed on the NASDAQ and all prices are listed in US Dollars. Fate Therapeutics employs 178 staff and has a trailing 12-month revenue of around USD$13.2 million.

How to buy shares in Fate Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Fate Therapeutics. Find the stock by name or ticker symbol: FATE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Fate Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$52.8, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Fate Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Fate Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Fate Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Fate Therapeutics's share price has had significant positive movement.

Its last market close was USD$52.8, which is 41.40% up on its pre-crash value of USD$30.94 and 215.22% up on the lowest point reached during the March crash when the shares fell as low as USD$16.75.

If you had bought USD$1,000 worth of Fate Therapeutics shares at the start of February 2020, those shares would have been worth USD$821.46 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,946.74.

Fate Therapeutics share price

Use our graph to track the performance of FATE stocks over time.

Fate Therapeutics shares at a glance

Information last updated 2020-10-19.
Latest market close USD$52.8
52-week range USD$13.26 - USD$51.1
50-day moving average USD$39.1338
200-day moving average USD$33.5707
Wall St. target price USD$39.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.222

Buy Fate Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fate Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fate Therapeutics price performance over time

Historical closes compared with the close of $52.8 from 2020-11-16

1 week (2020-11-23) -2.74%
1 month (2020-10-30) 18.92%
3 months (2020-08-28) 46.75%
6 months (2020-05-29) 62.81%
1 year (2019-11-29) 238.03%
2 years (2018-11-30) 243.75%
3 years (2017-11-30) 1,100.00%
5 years (2015-11-30) 1,160.14%

Fate Therapeutics financials

Revenue TTM USD$13.2 million
Gross profit TTM USD$-77,090,000
Return on assets TTM -17.49%
Return on equity TTM -38.73%
Profit margin 0%
Book value $5.462
Market capitalisation USD$4.1 billion

TTM: trailing 12 months

Shorting Fate Therapeutics shares

There are currently 13.9 million Fate Therapeutics shares held short by investors – that's known as Fate Therapeutics's "short interest". This figure is 7.6% up from 12.9 million last month.

There are a few different ways that this level of interest in shorting Fate Therapeutics shares can be evaluated.

Fate Therapeutics's "short interest ratio" (SIR)

Fate Therapeutics's "short interest ratio" (SIR) is the quantity of Fate Therapeutics shares currently shorted divided by the average quantity of Fate Therapeutics shares traded daily (recently around 1.1 million). Fate Therapeutics's SIR currently stands at 12.62. In other words for every 100,000 Fate Therapeutics shares traded daily on the market, roughly 12620 shares are currently held short.

However Fate Therapeutics's short interest can also be evaluated against the total number of Fate Therapeutics shares, or, against the total number of tradable Fate Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fate Therapeutics's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Fate Therapeutics shares in existence, roughly 160 shares are currently held short) or 0.2235% of the tradable shares (for every 100,000 tradable Fate Therapeutics shares, roughly 224 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Fate Therapeutics.

Find out more about how you can short Fate Therapeutics stock.

Fate Therapeutics share dividends

We're not expecting Fate Therapeutics to pay a dividend over the next 12 months.

Fate Therapeutics share price volatility

Over the last 12 months, Fate Therapeutics's shares have ranged in value from as little as $13.26 up to $51.1. A popular way to gauge a stock's volatility is its "beta".

FATE.US volatility(beta: 1.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fate Therapeutics's is 1.5654. This would suggest that Fate Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fate Therapeutics overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site